Radiotherap. is a mainstay of cancer treatment and improvements in efficacy are long awaited. DNA-dependent protein kinase (DNA-PK) is a key driver of one of the main DNA repair pathways. Zenke and colleagues report a new generation, potent, selective, and orally bioavailable DNA PK inhibitor, M3814. This agent effectively blocks the repair of DNA double-strand breaks and strongly potentiates the efficacy of ionizing radiation in multiple cancer cell lines. M3814 in combination with fractionated radiation treatment was well tolerated and led to effective human tumor regression in mouse xenograft models. M3814 may offer a novel treatment modality in combination with radiotherapy.

Transgenic mouse models of breast cancer have demonstrated that despite only moderate levels of infiltrating lymphocytes, significant levels of anti-tumor IgG antibodies are present. Knowing that a fucosylation of antibodies markedly enhances antibody-dependent cellular cytotoxicity (ADCC), Disis and colleagues employed the fucosylation inhibitor 2FF in these breast cancer models....

You do not currently have access to this content.